Phaseline

Targets › PSMB1

PSMB1 (Proteasome subunit beta type-1): drug programs, companies and trials

20 programs from 20 companies in 117 trials: 68 Phase 2, 29 Phase 1, 16 Phase 3, 4 Phase 4; Oncology, Metabolic and endocrine, Neurology; next expected readout Dec 2026.

Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. (UniProt, P20618)

Open in Phaseline: the race on PSMB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Second Affiliated Hospital, Zhejiang University, School of MedicineIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 4Multiple MyelomaJul 2028
University of LeedsIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 3Multiple MyelomaMar 2027
University of ArkansasBortezomib D-Mannitol
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 3Multiple Myeloma; MyelomaAug 2027
Regeneron PharmaceuticalsCarfilzomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 3Relapsed and/or Refractory Multiple Myeloma (RRMM)May 2029
Alliance Foundation Trials, LLC.Ixazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Myeloma, MultipleDec 2026
Washington University School of MedicineIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Multiple MyelomaAug 2027
Tel-Aviv Sourasky Medical Centerixazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Multiple Myeloma in RelapseSep 2027
European Myeloma Network B.V.Ixazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Multiple MyelomaSep 2027
M.D. Anderson Cancer CenterIxazomib Citrate
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Recurrent Plasma Cell Myeloma; Metastatic Urothelial CarcinomaOct 2027
Raija SilvennoinenIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Multiple MyelomaDec 2027
University of WashingtonIxazomib Citrate
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Chronic Lymphocytic LeukemiaJan 2028
Karyopharm TherapeuticsBortezomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Multiple Myeloma, Refractory; Hematological Neoplasms; Newly Diagnosed; Multiple Myeloma …Jan 2028
AIDS Malignancy ConsortiumIxazomib Citrate
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Kaposi SarcomaMar 2029
Nantes University HospitalIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Multiple Myeloma at First RelapseJan 2030
Memorial Sloan Kettering Cancer CenterIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2AL Amyloidosis–
Omar Nadeem, MDIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 1Multiple MyelomaJan 2027
Queen Mary University of LondonIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 1Relapsing Remitting Multiple SclerosisJul 2027
PfizerCarfilzomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 1Multiple Myeloma; Newly Diagnosed; Plasma Cell Myeloma; Newly Diagnosed Multiple Myeloma …Feb 2028
National Cancer Institute (NCI)Ixazomib Citrate
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 1Recurrent AL AmyloidosisJun 2028
Therapeutic Advances in Childhood Leukemia ConsortiumIxazomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 1ALL, Childhood–

Conditions

Multiple Myeloma (35) Plasma Cell Myeloma (5) Recurrent Plasma Cell Myeloma (5) Myeloma (3) Plasma Cell Leukemia (3) Newly Diagnosed (2) Newly Diagnosed Multiple Myeloma (2) Multiple Myeloma in Relapse (2) Recurrent Multiple Myeloma (2) Smoldering Multiple Myeloma (2) Waldenstrom Macroglobulinemia (2) Refractory Multiple Myeloma (2)

Modalities

small molecule (10), mixed (9)

Companies

University of Arkansas (1) National Cancer Institute (NCI) (1) Pfizer (1) AIDS Malignancy Consortium (1) University of Leeds (1) University of Washington (1) Queen Mary University of London (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Nantes University Hospital (1) Raija Silvennoinen (1) Karyopharm Therapeutics (1) Omar Nadeem, MD (1) European Myeloma Network B.V. (1) Memorial Sloan Kettering Cancer Center (1) M.D. Anderson Cancer Center (1) Tel-Aviv Sourasky Medical Center (1) Alliance Foundation Trials, LLC. (1) Regeneron Pharmaceuticals (1) Therapeutic Advances in Childhood Leukemia Consortium (1) Washington University School of Medicine (1)

Related targets

PSMD1 (20) PSMB2 (20) PSMB5 (20) PSMB8 (20)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.